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Purpose: To review the pathophysiology of coagulopathy in 
massively transfused, adult and previously hemostatically com-
petent patients in both elective surgical and trauma settings, and 
to recommend the most appropriate treatment strategies.
Methods: Medline was searched for articles on “massive trans-
fusion,” “transfusion,” “trauma,” “surgery,” “coagulopathy” and 
“hemostatic defects.” A group of experts reviewed the findings.
Principal findings: Coagulopathy will result from hemodilu-
tion, hypothermia, the use of fractionated blood products and 
disseminated intravascular coagulation. The clinical significance 
of the effects of hydroxyethyl starch solutions on hemostasis 
remains unclear. Maintaining a normal body temperature is a 
first-line, effective strategy to improve hemostasis during mas-
sive transfusion. Red cells play an important role in coagulation 
and hematocrits higher than 30% may be required to sustain 
hemostasis. In elective surgery patients, a decrease in fibrinogen 
concentration is observed initially while thrombocytopenia is a 
late occurrence. In trauma patients, tissue trauma, shock, tissue 
anoxia and hypothermia contribute to the development of dis-
seminated intravascular coagulation and microvascular bleeding. 
The use of platelets and/or fresh frozen plasma should depend 
on clinical judgment as well as the results of coagulation testing 
and should be used mainly to treat a clinical coagulopathy.
Conclusions: Coagulopathy associated with massive transfu-
sion remains an important clinical problem. It is an intricate, 
multifactorial and multicellular event. Treatment strategies 
include the maintenance of adequate tissue perfusion, the cor-
rection of hypothermia and anemia, and the use of hemostatic 
blood products to correct microvascular bleeding.
Objectif-: Revoir la physiopathologie de la coagulopathie chez les 
adultes transfusés massivement et auparavant compétents sur le 
plan hémostatique, à la fois dans le contexte d’une intervention 
chirurgicale réglée ou à la suite d’un traumatisme. Recommander 
les stratégies thérapeutiques les plus appropriées.
Méthode-: Dans Medline, nous avons cherché les articles 
traitant de “massive transfusion,” “transfusion,” “trauma,” 
“surgery,”“coagulopathy” et “hemostatic defects.” Un groupe 
d’experts a examiné les résultats.
Constatations principales-: La coagulopathie résulte de l’hémo- 
dilution, l’hypothermie, l’usage de produits sanguins fractionnés et 
la coagulation intravasculaire disséminée. La portée clinique des 
effets des solutions d’hydroxyéthyl-amidon sur l’hémostase n’est 
toujours pas claire. Le maintien d’une température corporelle nor-
male est une stratégie de première intention efficace pour amélio-
rer l’hémostase pendant la transfusion massive. Les globules rouges 
sont importants dans la coagulation et des hématocrites supérieurs 
à 30 % pourraient être nécessaires à une hémostase adéquate. 
Chez les patients en chirurgie réglée, une baisse de la concen-
tration de fibrinogène est observée précocement tandis que la 
thrombocytopénie est plus tardive. Chez les traumatisés, le trauma 
tissulaire, le choc, l’anoxie et l’hypothermie tissulaires contribuent 
au développement d’une coagulation intravasculaire disséminée et 
du saignement microvasculaire. L’utilisation de plaquettes et/ou de 
plasma frais congelé dépendra du jugement du clinicien ainsi que 
des résultats des tests de coagulation. La transfusion devra sur-
tout viser le traitement d’une coagulopathie clinique (saignement 
microvasculaire).
Conclusion-: La coagulopathie associée à la transfusion massive 
demeure un important problème clinique. C’est un événement 
complexe, multifactoriel et multicellulaire. Le traitement comprend 
le maintien d’une perfusion tissulaire adéquate, la correction de 
l’hypothermie et de l’anémie et l’usage de produits sanguins hémo-
statiques pour corriger le saignement microvasculaire.
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List of abbreviations
aPTT activated partial thromboplastin time
BT bleeding time
DIC disseminated intravascular coagulation
FFP fresh frozen plasma
HES hydroxyethyl starch
MT  massive transfusion
MVB microvascular bleeding
MWB modified whole blood
PRBC packed red blood cells
PT prothrombin time
RBC red blood cells
U
NCONTROLLED hemorrhage, and by 
way of consequence, massive transfu-
sion (MT) is a frequent complication of 
trauma and surgery. MT is commonly 
defined as the replacement of one blood mass in a 
period of 24 hr. A dynamic definition of MT, such as 
the transfusion of four or more red cell concentrates 
within one hour when ongoing need is foreseeable,1 
or the replacement of 50% of the total blood volume 
within three hours, is more relevant in the acute 
clinical setting. Massively transfused patients will show 
evidence of defective hemostasis in a high percent-
age of cases. In this review, the term “coagulopathy” 
is used interchangeably with the more general term 
“defective hemostasis” and encompasses both defects 
of primary hemostasis (related to platelet function) 
and coagulopathy (related to alterations of the plasma 
phase of coagulation).
The incidence of hemostatic defects associated with 
MT will vary according to the clinical context (blunt vs 
penetrating trauma, presence of brain injury, elective 
surgery),2,3 according to the definition of coagulopa-
thy (clinical findings vs laboratory test results),3 and 
according to the blood products administered to the 
massively bleeding patient (fresh whole blood, stored 
whole blood, “modified whole blood” (MWB-whole 
blood from which platelets and/or cryoprecipitate 
are salvaged before storage),4,5 packed red blood cells 
(PRBC), concentrated red cells, etc.).6 For example, 
prior to the era of blood fractionation, the transfusion 
of large volumes of stored blank blood did not result 
in a hemorrhagic diathesis in young and previously 
healthy soldiers wounded during the Vietnam war.7 
More recently, it has been shown that abnormalities 
of the prothrombin time (PT) and of the activated 
partial thromboplastin time (aPTT) occur after the 
transfusion of 12 units of PRBC and that thrombo-
cytopenia develops after the transfusion of 20 units.8 
Yet, despite several attempts at defining meaningful 
laboratory indicators of impending or established 
coagulopathy, the relationship between laboratory 
hemostatic abnormalities and abnormal clinical bleed-
ing remains unclear.
Most studies of MT have been conducted in 
trauma patients and most are retrospective or uncon-
trolled observational studies,9 for obvious reasons. 
Given the variable and complex clinical context, the 
results of these studies have seldom led to defini-
tive conclusions. Furthermore, factors other than 
the transfusion strategy, related to trauma itself, may 
have led to the observed hemostatic abnormalities.10 
Unfortunately, conventional teaching has sometimes 
failed to appreciate the evolution of transfusion prac-
tices and the context in which these were developed. 
As a result, anesthesiologists may have been led to 
apply transfusion strategies, e.g., those developed for 
trauma patients at a time when MWB was available,5,11 
inappropriately to patient receiving red cell concen-
trates for massive bleeding during elective surgery. 
The situation may become even more confusing when 
disseminated intravascular coagulation (DIC) is asso-
ciated with trauma and/or MT.
In this article on MT and coagulopathy, we will 
attempt to review:
- 1. the pathophysiology of coagulopathy in mas-
sively transfused, adult and previously hemostatically 
competent patients in both the elective surgical and 
trauma settings; and
- 2. the management strategies used in these set-
tings.
We searched Medline for original articles published 
on “massive transfusion,” “transfusion,” “trauma,” 
“surgery,” “coagulopathy” and “hemostatic defects.” 
In addition, the reference lists of obtained articles were 
searched to identify other relevant articles. This review 
does not deal with the obstetrical and pediatric patient 
populations, nor with specific hemostatic anomalies 
such as those associated with cardiopulmonary bypass 
(CPB), liver transplantation and pre-existing coagu-
lation disorders. Nevertheless, when relevant to the 
discussion, a few articles from those areas have been 
included in the review.
A preliminary version of the text was circulated 
to experts of the “Groupe d’intérêt en hémostase 
périopératoire” [Perioperative Hemostasis Interest 
Group] for comments and suggestions at a meeting of 
the GIHP held in La Fouly, Switzerland, in February 
2003. A narrative format was adopted since the het-
erogeneity of published studies is considerable and 
was not conducive to a more formal review. Because 
the nature of blood products available to clinicians 
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has changed over time, the retrieved articles were 
organized and reviewed by date of publication, to 
understand the evolution of our knowledge on MT 
and coagulopathy.
I. Pathophysiology of coagulopathy in MT
Volume replacement with crystalloids and colloids and 
temperature control are initial resuscitation measures; 
these are followed by the transfusion of red cells, 
coagulation factors and platelets; finally, DIC may 
become a problem that will require treatment.
A. Hemodilution
1. CRYSTALLOIDS
In elective surgery, rapid hemodilution with crystalloids 
has been shown to induce changes on thromboelastog-
raphy suggestive of increased thrombin generation and 
a hypercoagulable state.12,13 The clinical significance 
of this effect, specially in trauma patients who are ini-
tially hypercoagulable,7 remains unclear. Nonetheless, 
crystalloid-induced hypercoagulability casts a doubt 
on studies of the effects of colloids on coagulation that 
used crystalloids as a control.14
2. COLLOIDS
The characteristics of the different colloids and their 
effects on coagulation are presented in Table I.
Gelatins have the reputation of not influencing 
coagulation other than by their hemodiluting effect.15,16 
Nonetheless, dilution of whole blood samples with 
two gelatin solutions resulted in a reduction of clot 
quality (less extensive fibrin mesh formation, reduced 
clot weight and mean shear modulus) compared to 
dilution with normal saline.17 In volunteers, 1 L of a 
gelatin-based plasma substitute significantly impaired 
primary hemostasis and thrombin generation compared 
to normal saline.18 A study comparing a 3% modi-
fied fluid gelatin to 6% hydroxyethyl starch (HES) in 
patients undergoing primary total hip replacement 
concluded that the gelatin-based plasma expander had 
a poorer volume effect than HES and that blood losses 
were less important with gelatin compared to HES.15 
Coagulation tests were similar in both groups except 
for the higher incidence of an abnormal bleeding time 
(BT) in the HES group. The clinical significance of 
these findings remains unclear. Perhaps the effects on 
coagulation of gelatin-based plasma substitutes are not 
clinically important. On the other hand, they may have 
been underestimated, given the difficulties of studying 
coagulation in the uncontrolled context of trauma, MT 
and ongoing bleeding.
HES solutions are effective plasma expanders in 
common use both in Europe and in North America. 
It has long been known that HES solutions interfere 
with coagulation19 and that the effects vary accord-
ing to the dose and type of solution administered.20 
Solutions with a high molecular weight and a high 
degree of substitution accumulate in the tissues and are 
responsible for more pronounced hemostatic effects.21 
Abnormal platelet function occurs more frequently 
after high molecular weight HES.22 Conversely, HES 
solutions with a low molecular weight and a lesser 
degree of substitution are eliminated more rapidly and 
tend to affect measures of hemostasis less.23–25
In addition to their effects on hemostasis, the infu-
sion of large volumes of HES solutions will result 
in significant hemodilution. The resulting drop in 
hemoglobin and platelet concentrations may com-
promise primary hemostasis. In addition, Innerhofer 
et al. have shown that the administration of HES or 
modified gelatin in patients undergoing knee replace-
ment surgery results in reduced clot strength due to 
impaired fibrinogen polymerization and that reduced 
fibrinogen concentrations might be reached earlier 
than expected.26
Adverse events associated with the use of HES 
solutions for the resuscitation of patients requiring 
MT have not been reported, inasmuch as the allowed 
maximal daily dose is not exceeded.16 A large retro-
spective study suggested that the use of 6% HES in 
primary cardiac surgery with CPB may increase bleed-
ing and transfusion requirements, despite the infusion 
of volumes smaller than the manufacturer’s recom-
mended dose.27 Conversely, large volumes (up to 5 L) 
have been infused without major complications,28 but 
the safety of this practice remains controversial.29
The clinical significance of the effects of HES solu-
tions on hemostasis remains unclear. It may never be 
possible to determine precisely the effect of volume 
replacement in massively transfused patients with ongo-
ing bleeding. In these patients, hemostasis is stressed 
severely by numerous factors other than the type of 
non-blood-related iv fluid used for resuscitation and the 
underlying cause of coagulopathy is difficult to ascer-
tain. Nonetheless, it is interesting to note that the use of 
colloids in trauma patients is not mentioned in the rec-
ommendations by the American College of Surgeons.30
B. Hypothermia
An important measure to reduce blood loss through 
preservation of hemostasis is the maintenance of nor-
mothermia both during and after the operation. The 
definition of hypothermia has varied amongst studies; 
however, most definitions have used temperatures 
below 35°C. Hypothermia slows the activity of the 
coagulation cascade, an enzymatic process, reduces 
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the synthesis of coagulation factors, increases fibrino-
lysis and affects platelet function.
1. ANIMAL DATA
Several animal studies conducted under hypother-
mic conditions have shown reversible platelet count 
decreases and platelet function defects, altered coagu-
lation patterns and an enhanced fibrinolytic response. 
In dogs cooled to 19°C, Yoshihara et al. found a 
severe decrease in platelet count and collagen-induced 
platelet aggregability and an increase in fibrinolysis.31 
No variations of the PT and aPTT were observed but 
these tests were performed in vitro at 37°C. These 
modifications, which could potentially increase bleed-
ing, were not documented in the normothermic con-
trol group. Other experimental studies have shown an 
important prolongation of the PT and aPTT that was 
inversely and linearly correlated to temperature.32,33
Pina-Cabral et al. also observed a decrease in 
platelet count in hypothermic dogs.34 The presence 
of platelet clumps was detected inside the hepatic 
sinusoids. The authors concluded that hepatic platelet 
sequestration could explain the decrease in platelet 
count in this setting.
In swine, Oung et al. showed a prolongation of 
the BT (10.9 min vs 5.5 min in the control group), 
confirming the impairment of hemostasis induced 
by hypothermia (30°C).35 Prolongation of the BT 
has also been observed by Valeri et al. in baboons 
subjected to systemic hypothermia at 32°C and skin 
hypothermia at 27°C.36
2. HUMAN DATA
In humans, many studies have emphasized the major 
role of hypothermia on the onset of bleeding during 
surgical procedures. Valeri et al. observed the effects 
of skin temperature in 33 patients undergoing CPB.37 
Local hypothermia produced an increased BT and a 
significant reduction in thromboxane B2, an indicator 
of platelet activation, at the BT site. Local rewarming 
produced a significant increase in shed blood throm-
boxane B2. Thus, hypothermia caused a reversible 
platelet dysfunction and rewarming improved platelet 
function and reduced the BT. These data have been 
confirmed by Michelson et al. who demonstrated the 
involvement of platelet glycoprotein receptor (GP Ib 
and GMP 140) alterations in this hemostatic defect.38 
Again, rewarming completely reversed the activation 
defect as soon as temperature returned to 37°C.
These abnormalities of routine coagulation tests are 
clinically significant: mild hypothermia (35 ± 0.5°C) 
increased bleeding and allogeneic blood requirements 
in patients undergoing total hip arthroplasty.39 Thus, 
surgery under normothermic conditions may help 
prevent bleeding complications and decrease the intra-
operative use of transfusions. The additional contribu-
TABLE I  Characteristics of the available colloids and their effects on coagulation
Product Commercial name Concentration % Oncotic pressure Initial volume Persistance in the  Maximal Effect on
   mmHg expansion % body (days) dose/24 hr hemostasis
Albumin  4 20–29 80   0
   20 100–120 200–400
Dextran 70 Macrodex 6 56–68 120 28–42 1.5 g·kg–1 +++
Dextran 40 Rheomacrodex 10 168–191 200 6 1.5 g·kg–1 +++
Fluid gelatin Gelofusine, Plasmion 3–4 42 70–90 7  0 to +
Urea linked gelatin Hemacel 3.5 25–29 70–80 2–7  0 to +
HES 450/0.7 Plasmasteril 6 24–30 100 120–182 20 mL·kg–1 +++
HES 200/0.62/10 Elohes 6 25–30 110 6–7 20 mL·kg–1 ++
HES 200/0.5/5 Hesteril 6 30–37 100 3–4 33 mL·kg–1 +
HES 200/0.5/5 Lomol, Hesteril 10 59–82 145 3–4 20 mL·kg–1 +
HES 130/0.4/11 Voluven 6 36 100–110  50 mL·kg–1 0 to +
Effect on hemostasis: 0 = none; + = weak; ++ = moderate; +++ = important. Commercial names are European. Some data are not avail-
able. In the “product” column, the first number is the molecular weight in Daltons, the second is the degree of substitution and the third 
is the C2/C6 ratio of hydroxyethylstarch (HES) substitution. The higher the molecular weight and the degree of substitution, the lon-
ger the plasma half-life and the effects on hemostasis. Adapted from Ickx, BE and Van der Linden P. Interactions entre solutés colloides 
et l’hémostase. Sang Thrombose Vaisseaux 2002; 7: 408–16 [article in French] Hetastarch (480/0.7), used in the USA, has important 
effects on hemostasis. Pentastarch (260/0.45), available in Canada, is similar to Hesteril 10% and has weak effects on hemostasis at the 
maximal dose (28 mL·kg–1) recommended by the manufacturer.
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tion of hypothermia to the hemorrhagic diathesis may 
be overlooked since coagulation testing is normally 
performed at 37°C.40
Hypothermia is an important contributor to coagu-
lopathy in trauma patients.41 Hypothermia (tempera-
ture less than 34°C) occurred in 80% of non-survivors 
and 36% of survivors in the 45 trauma patients report-
ed by Ferrara et al.42 Patients who were hypothermic 
and acidotic developed clinically significant bleeding 
despite adequate blood, plasma, and platelet replace-
ment. The authors concluded that avoidance or cor-
rection of hypothermia may be critical in preventing 
or correcting coagulopathy in the patient receiving 
MT.
C. Blood components and alterations of hemostasis
1. RED CELLS
An often-ignored effect of red blood cell (RBC) 
transfusion is the improvement of hemostatic func-
tion. The contributions of RBC to hemostasis are 
illustrated in Figure 1.
Erythrocytes have been shown to modulate the 
biochemical and functional responsiveness of acti-
vated platelets, suggesting that erythrocytes contrib-
ute to thrombosis and hemostasis and supporting the 
concept that thrombus formation is a multicellular 
event.43–45 Red cells contain adenosine diphosphate 
that may activate platelets.46 Also, they activate platelet 
cyclooxygenase,44 increase the generation of throm-
boxane A244 and may directly increase the thrombin 
burst through exposure of procoagulant phospholip-
ids.47 This proaggregatory property of erythrocytes is 
enhanced by diabetes48 and can be decreased by an 
appropriate aspirin regimen.49,50
Another mechanism by which erythrocytes modu-
late hemostasis is the rheological effect of red cells on 
the margination of platelets.51 Under normal circum-
stances, red cell flow is maximal at the centre of a ves-
sel, tending to push platelets towards the periphery of 
the vessel lumen, thereby optimizing their interaction 
with injured endothelium and promoting hemosta-
sis. In rabbit arterioles, platelet numbers are highest 
near the vessel wall52 and platelets align themselves 
with their equatorial plane parallel to the vessel wall 
as they move closer toward the periphery of the ves-
sel.53 Experimental data have shown that platelets are 
expelled toward the RBC depleted marginal layer near 
the tube wall by mutual interaction with erythrocytes. 
Under these circumstances, the near wall concentra-
tion of platelets is enhanced up to about seven times 
the average concentration.54
The correlation between the BT and hematocrit 
levels has been studied experimentally. In non-throm-
bocytopenic rabbits, the microvascular BT varied 
inversely with the hematocrit, animals with hematocrit 
levels above 35% having shorter BTs than animals 
with hematocrits lower than 35%.55 In a rabbit model 
of cyclic arterial thrombosis and clot lysis, Ouaknine-
Orlando et al. have shown that decreases in the hema-
tocrit reduced the cyclic arterial thrombosis rate and 
increased the BT.46 Interestingly, normalization of the 
hematocrit caused thrombosis to reappear.
Transfusion of RBC shortens the BT in anemic 
thrombocytopenic patients despite persistent throm-
bocytopenia.56 Further, perfusion of blood from trans-
fused, previously anemic thrombocytopenic patients 
improved the interaction of platelets with the subendo-
thelium in an experimental perfusion model. However, 
this interaction remained lower than in non-ane-
mic non-thrombocytopenic subjects.56 Similarly, RBC 
shorten the BT and control the hemorrhagic diathesis 
of uremic patients.57 In humans with a normal renal 
function and platelet counts over 100,000·mm-3, a 
modest but statistically significant inverse correlation (r 
= -0.47; P < 0.001) exists between the hematocrit and 
the BT.58 Patients with a pretransfusion hemoglobin 
concentration ≤ 60 g·L–1 have a greater chance (relative 
risk 4.07; 95% confidence interval 1.03 to 16.2; P = 
0.04) of a posttransfusion decrease in BT than patients 
with a hemoglobin of more than 60 g·L–1.59 Valeri et al. 
have shown that, in healthy volunteers, an acute 15% 
FIGURE 1  The contribution of red cells to hemostasis 
Red cells contribute to the margination of platelets against the 
vessel wall and their availability to act at the site of a vascular 
lesion. They have also been shown to modulate the biochemical 
and functional responsiveness of activated platelets. (Courtesy of 
Sylvain Bélisle, MD, FRCPC, Montreal Heart Institute).
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reduction in hematocrit produced a 60% increase in the 
BT while the BT remained normal despite a 32% reduc-
tion in platelet count.60 All this being said, the clinical 
significance of these findings remains unclear since the 
relationship between the BT and perioperative blood 
losses is highly controversial.60,61
The hemostatic effects of profound normovole-
mic hemodilution were investigated in eight patients 
undergoing surgical correction of idiopathic sco-
liosis by McLoughlin et al.62 Abnormal hemostasis 
developed prior to compromise of global tissue 
oxygenation suggesting that, in healthy anesthetized 
subjects, normovolemic hemodilution may be limited 
more by preservation of normal coagulation. In this 
report, reinfusion of all collected blood at the end 
of the procedure did not normalize the PT or the 
aPTT. Unfortunately, the authors did not describe if 
the microvascular bleeding (MVB) observed during 
hemodilution was corrected by increasing the hema-
tocrit. Modified ultrafiltration in pediatric open heart 
operations has been shown to increase the hematocrit 
and attenuate the dilutional coagulopathy associated 
with CPB in infants.63 Use of modified ultrafiltration 
to increase the hematocrit to 36–42% reduced the rise 
in total body water and the need for donor blood in 
children undergoing open heart surgery.64
Thus, further investigations into the role of the 
hemoglobin concentration or hematocrit on hemosta-
sis in massively transfused patients appear warranted. 
The data presented above tend to support the con-
cept of a minimal hematocrit for optimal hemostasis. 
At present the optimal hematocrit or hemoglobin 
concentration to prevent or to initiate treatment of 
coagulopathy remains unknown. Experimental evi-
dence suggests that relatively high hematocrits, pos-
sibly as high as 35%, are required to sustain hemostasis 
in bleeding patients undergoing MT.
2. COAGULATION FACTORS
It is difficult to isolate precisely the role of coagulation 
factors in the pathophysiology of coagulopathy associ-
ated with MT. Impaired hemostasis is most probably 
multifactorial in origin and results from the adverse 
hemostatic effect of multiple concurrent coagulation 
factor deficits combined with variable degrees of ane-
mia and thrombocytopenia.6
While numerous studies have measured changes in 
the PT and aPTT in relationship with bleeding and 
MT, few have examined individual hemostatic factors. 
In 1979, transfusing MWB to patients who sustained 
major trauma, massive gastrointestinal hemorrhage or 
aortic aneurysm rupture, Counts et al. reported that 
the number of units of blood transfused explained less 
than 20% of the variance in factors V and VIII and was 
not related to factor VII, X, XI, XII and fibrinogen 
levels. The authors concluded that it was not neces-
sary to supplement transfusions of stored, MWB with 
fresh blood or fresh frozen plasma (FFP).5 In 1995, 
using plasma poor red cell concentrates, Hiippala et 
al. showed that a concentration of fibrinogen of 1.0 
g·L–1 was reached when the blood loss was 1.42 times 
the calculated blood volume and that blood losses in 
excess of two blood volumes caused the deficiency of 
prothrombin, factor V, platelets and factor VII, in this 
order.65 These observations were made in ASA physi-
cal status I or II patients undergoing elective major 
urologic or abdominal surgery and, as a result, may not 
apply to emergent operations or trauma. Nonetheless, 
they illustrate well the difference between the times 
when red cell solutions contained significant amounts 
of plasma and modern component therapy.
It is important to realize that studies conducted at 
a time when fresh, stored or modified MWB was in 
common use seldom reported low levels of coagulation 
factors as the primary factor responsible for impaired 
hemostasis.4,5,7,11,66 Since the widespread use of red cell 
solutions containing minimal amounts of plasma in the 
late 1980’s and early 1990’s, dilution or consumption 
of coagulation factors has become a significant issue 
requiring specific treatment with, primarily, FFP.3,6,8,65 
Even today, clinicians seldom administer “pure” blood 
products. PRBC contain a small amount of plasma (30–
60 mL), as do platelet concentrates (80 mL approxi-
mately). Therefore, it may be difficult to differentiate 
precisely the therapeutic effect of the different blood 
components transfused.
3. PLATELETS
Primary hemostasis is characterized by the formation 
of the “platelet plug.” The mechanism is complex 
and involves the presence of fibrinogen and activa-
tion of several glycoprotein receptors on platelets.67–71 
Hemostasis is initiated by injury to the vascular wall, 
leading to the deposition of platelets adhering to 
blood vessel subendothelial matrix proteins (collagen 
and von Willebrand factor) via interactions with plate-
let membrane glycoprotein receptors. Subsequently, 
the GP IIb/IIIa receptor is activated. This receptor 
has a high affinity for fibrinogen (and also for von 
Willebrand factor at high shear stress). Binding of 
fibrinogen to adjacent platelets results in irreversible 
platelet aggregation and the formation of the platelet 
aggregate.
Since the publication of Miller’s classic study on 
coagulation defects associated with massive blood 
transfusions,11 thrombocytopenia resulting from 
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hemodilution has been thought to be the most 
important hemostatic abnormality associated with 
MT. This explanation is intuitively appealing: replace-
ment of lost blood with fluids that do not contain 
platelets (or coagulation factors) results in a dilutional 
coagulopathy. However, models based on the washout 
equation (a simple mathematical model of exchange 
transfusion that calculates the decay of blood com-
ponents when bleeding and replacement rates are 
constant and equal) may not apply to bleeding trauma 
patients where blood volumes fluctuate, bleeding rates 
vary with blood pressure, and replacement often lags 
behind blood loss.72 Clinically, simple hemodilution 
has failed to explain several observations.
In young, previously healthy soldiers with wounds 
excluding burns and head injuries, platelet levels fell 
rapidly to about 100,000·mm-3 during rapid transfu-
sion of stored whole blood and remained at that level 
after the first 6 L of stored whole blood. The PT, aPTT 
and fibrinogen levels were less severely affected and, 
most important, significant operative bleeding was not 
encountered in conjunction with these mild dilutional 
coagulation changes.7 On average, the platelet count 
fell below 100,000·mm-3 after transfusion of 18 units 
of blood in the study by Counts et al.,5 but slightly less 
than half (43%) of the variation in platelet counts could 
be ascribed to the functional relationship between the 
amount of blood transfused and the platelet count. In 
a study conducted to determine the efficacy of prophy-
lactic platelet administration to prevent MVB associated 
with MT, Reed et al. observed that platelet counts were 
not different between patients who received prophylac-
tic platelet transfusions and those who did not.4 Further, 
both groups had higher platelet counts than predicted 
by a standard washout equation. This finding implies 
that platelets are being released into the circulation and 
counteract the effects of dilution. Sequestered platelets 
can be released from the spleen and the lung, in addi-
tion to the premature release of platelets from the bone 
marrow. Elevated stress hormones and the administra-
tion of catecholamines, a situation more likely to occur 
in the trauma patient, will influence release.
As in the study by Counts, Reed et al. found the 
relationship between platelet counts and units of blood 
transfused to be significant albeit highly variable (r2 = 
0.24 for patients receiving platelets and r2 = 0.35 for 
patients receiving FFP),4 suggesting that factors other 
than simple dilution affect platelet count. Finally, in 
the study by Miller, observed platelet counts did not 
parallel calculated platelet counts (Figure 2).11
In elective surgery, the situation appears to be 
quite different, possibly because tissue trauma is more 
controlled, normovolemia is maintained and blood 
losses are replaced in a timely manner. In this context, 
coagulopathy is primarily related to a coagulation 
factor deficit3,65 and the role of fibrinogen appears to 
be preponderant. The deficiency in fibrinogen con-
centration develops earlier than any other hemostatic 
abnormality when plasma-poor red cell concentrates 
and colloid plasma substitutes are used for the replace-
ment of major blood loss. Approximately 90% of the 
variation in fibrinogen concentration is explained by 
blood loss and the critical level of 1.0 g·L–1 is reached 
when blood losses reach 142% (95% confidence inter-
val 117%–169%) of the calculated blood volume.65 
In this same study, thrombocytopenia (defined as a 
platelet count below 50,000·mm-3) was a late occur-
rence and, to a great extent, quite variable from 
patient to patient. Murray et al. studied coagulation 
changes during crystalloid and PRBC replacement of 
major blood loss during elective surgery.73 Four out 
of 12 patients presented a coagulopathy. All patients 
FIGURE 2  Calculated vs observed platelet counts in a person 
receiving platelet-free blood 
Observed platelet counts are higher than those predicted by 
hemodilution alone: the observed platelet count after the admin-
istration of 25 units of blood is of the order of 60,000·mm–3 
while hemodilution predicted a platelet count of approximately 
20,000·mm–3. Reproduced with permission from Miller RD, 
Robbins TO, Tong MJ, Barton SL. Coagulation defects associated 
with massive blood transfusions. Ann Surg 1971; 174: 794–801.
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with inadequate clinical hemostasis had a low platelet 
count (83,000·mm-3 or below) and transfusion of 
platelet concentrates corrected the problem in the 
two who had fibrinogen concentrations above 1.0 
g·L–1. Of note, platelet transfusion was ineffective 
in the two patients with concurrent low fibrinogen 
concentrations (0.73 and 0.40 g·L–1). The subsequent 
transfusion of two and four units of FFP (respectively) 
normalized hemostasis. The report by Ciavarella et 
al. supports the association between MVB and a low 
platelet count (below 50,000·mm-3) or a low fibrino-
gen concentration (below 0.5 g·L–1).66
Thus, it appears logical to consider that coagu-
lopathy after MT can be a problem resulting from a 
combined deficit of platelets and fibrinogen. Focusing 
only on platelet levels or concentrations of specific 
coagulation factors may not lead to the most appropri-
ate therapeutic approach.
D. DIC
1. DEFINITION
DIC is an acquired syndrome secondary to the sys-
temic and excessive activation of coagulation. It may be 
defined by the association of hemostatic defects related 
to the exaggerated generation of thrombin and fibrin 
(with or without clinical signs) and the excessive con-
sumption of platelets and coagulation factors. Criteria 
for the diagnosis of DIC are presented in Table II. The 
syndrome can be seen in numerous clinical situations 
and often complicates the management of MT.
2. THE TRAUMA SETTING
In earlier studies of trauma patients, DIC leading to 
MVB was, apparently, relatively infrequent, occurring 
for example in one out of 21 patients11 and three out 
of 27 patients.5 In wounded, previously healthy, sol-
diers requiring MT, DIC was mild and was not associ-
ated with clinical bleeding.7,11 Recent studies suggest 
that there is no significant correlation between total 
TABLE II  Diagnostic criteria for disseminated intravascular coagulation (DIC)
Classification Definition Diagnostic criteria Details of laboratory criteria
Biological DIC Hemostatic defect Elevated D-Dimers D-Dimers greater
 without clinical and than 500 µg·L–1
 manifestations
  1 major criterion for Platelet consumption
  consumption of Minor: platelet count
  platelets or between 50 and
  coagulation factors 100,000·mm–3
  or Major: platelet count less than  
  2 minor criteria for 50,000·mm–3
  consumption of platelets or
  coagulation factors
Clinical DIC Hemostatic defect with Same as above + Consumption of coagulation
 hemorrhagic or microvascular bleeding and/or factors
 ischemic manifestations thrombosis Minor: INR of the PT between  
 
   1.2 and 1.5
   Major: INR of the PT greater  
   than 1.5
Complicated DIC Hemostatic defect with Same as above +
 hemorrhagic or organ failure (single or multiple)
 ischemic manifestations
 that jeopardize organ
 function or patient
 prognosis
INR of the PT = international normalized ratio of the prothrombin time.The elevation of D-Dimers is not specific to DIC. Similarly, 
the clinical manifestations of DIC are not specific. Adapted from the Proceedings of the XXIInd consensus conference of the “Société de 
Réanimation de Langue Française” held in Lille, France, in October 2002 and published in Réanimation 2002; 11: 575–666. A French 
summary is available at www.srlf.org/conferences/XXII-conf-Lille.html.
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units of blood transfused and the severity of impaired 
hemostasis, suggesting that consumption of coagu-
lation factors and platelets is more important than 
simple hemodilution.41,74,75
In trauma patients, two major mechanisms are 
responsible for the occurrence of DIC. The first 
relates to the nature and to the importance of tissue 
trauma. The second relates to shock and tissue anoxia. 
Brain injury is associated with a particularly high inci-
dence of coagulopathy. In the study by Faringer et al., 
more than 40% of patients with penetrating or blunt 
trauma with associated brain injuries had abnormal 
coagulation tests on admission, compared with 0% in 
patients with blunt trauma but without brain injury.2 
After blunt brain injury, a DIC syndrome secondary 
to the extravasation of tissue factor can rapidly (within 
one to four hours after injury) lead to a consumptive 
coagulopathy that is associated with a high frequency 
of death.76 Regarding the importance of tissue trauma, 
in the absence of massive head injury and pre-existing 
disease, life-threatening coagulopathy was associated 
with a pH of less than 7.10, a temperature of less than 
34°C, an injury severity score greater than 25, and a 
systolic blood pressure of less than 70 mmHg. When 
all risk factors were present, the incidence of coagu-
lopathy was 98%.41
At least two studies have attempted to determine 
which populations of massively transfused patients 
are most at risk of sustaining DIC. Mannucci et al. 
studied changes in the hemostatic system in 172 
patients undergoing MT for excessive bleeding dur-
ing or in the early postoperative period after elective, 
emergent or trauma surgery. Of these, 52 (30%) suf-
fered decompensated DIC and there was no signifi-
cant relation between the number of whole blood or 
PRBC units transfused and the values of any variable 
of hemostasis measured.77 In a series of 64 patients 
receiving more than ten units of red cell concentrates 
during elective or urgent surgical procedures or resus-
citation of multiple trauma, Hewson et al. observed 
that coagulopathy is related to hemodilution initially, 
but, within three hours, is related to the duration of 
antecedent hypotension. Thus, on the basis of the 
available information, it is difficult to determine which 
patient population (elective or urgent operations, 
trauma) is most likely to sustain DIC.
3. THE ELECTIVE SURGICAL SETTING
In the purely elective setting, DIC complicating MT is 
infrequent. No patient suffered from DIC amongst the 
32 young ASA physical status I or II patients undergo-
ing posterior spinal stabilization and MT.3 Clinically 
increased surgical bleeding was present in 17 patients 
and in 14 of the 17 patients hemostasis improved after 
the administration of FFP (approximately 10 mL·kg–1). 
Again, these results suggest that when tissue anoxia is 
avoided and surgical trauma is controlled, the occur-
rence of DIC may remain low despite MT.
III. Management of coagulopathy in MT
A. Diagnosis
Numerous attempts have been made to monitor 
changes of the coagulation system in relationship to 
trauma, surgery and MT. Unfortunately, results have 
been disappointing and, at present, there is no simple, 
reliable and rapid diagnostic test that allows clinicians 
to manage massively transfused, critically ill patients. 
The available tests quantify specific factors in clotting 
or attempt to measure clotting function.
The platelet count is the only indicator of coagula-
tion that can be obtained rapidly through the use of 
automated counters, in contrast to conventional tests 
of hemostasis that take a minimum of 30 min since 
they require centrifugation of blood samples. Even 
if platelets play an important role in coagulation, a 
decreased platelet count is not a specific indicator of 
coagulopathy. Rather, the significance of a decreased 
platelet count should be interpreted in the patient’s 
specific clinical context: is platelet function expected 
to be normal? Is the fibrinogen concentration suf-
ficient? Is the hemoglobin concentration adequate? 
Is there any evidence of a consumptive coagulopathy? 
Answering these questions will assist in making the 
appropriate diagnosis of coagulopathy.
Usefulness of the BT to diagnose or predict coagu-
lopathy in massively transfused patients has been inves-
tigated in a few studies. Overall, the BT increases early 
in the course of surgery and transfusion,78 remains 
elevated for several days postoperatively79 and does 
not allow the differentiation between bleeding and 
non-bleeding patients.5 In their critical reappraisal of 
the BT, Rodgers and Levin concluded that there is 
no evidence that abnormalities in the test occur suf-
ficiently in advance of other indicators of bleeding to 
allow actions to be taken that could alter outcome 
favourably.80 Consequently, the BT is of no use in the 
context of MT.
Reliable bedside monitors have become available to 
monitor the PT and aPTT81 and may add to the timely 
management of the bleeding patient. Controversy 
remains, though, on the proper use of coagulation 
screening tests to guide replacement therapy. The PT 
and aPTT are expected to become elevated when lev-
els of factor V, VIII and IX are less than 50% of values 
found in a control patient population.82 It should be 
noted, however, that the PT and aPTT are prolonged 
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when fibrinogen levels are low in the presence of 
normal concentrations of coagulation factors (e.g., 
congenital afibrinogenemia).
As for decreased platelet counts and prolongations 
of the BT, prolongations of the PT and aPTT are very 
common in massively transfused patients.2,3,5,7,8,11,41,6
5,73,75,77,83,84 Minor prolongations of the PT or aPTT 
ratio (ratio = measured value/control value) are poor 
predictors of bleeding in massively transfused patients.5 
Ciavarella et al. have shown that, in 36 massively trans-
fused patients, patients with a PT or aPTT ratio greater 
or equal to 1.8 had an 80 to 85% chance of exhibiting 
MVB.66 When the fibrinogen level is adequate, a PT or 
aPTT ratio greater or equal to 1.8 reliably predicts that 
factor V and VIII levels are less than 30%,66 a percent-
age that has been cited as an indication for coagulation 
factor replacement.4,66 In the presence of a decreased 
fibrinogen concentration (less than 0.75 g·L–1), a PT or 
aPTT ratio greater than 1.5 is associated with factors V 
and VIII of less than 20%.73
In summary, only marked prolongations of the PT 
or aPTT (1.5 and 1.8 times higher than control when 
the fibrinogen level is low and normal respectively) are 
likely to be significant from a clinical perspective.
Other instruments have been developed to study 
coagulation at the bedside, using whole blood. While 
their use in the context of MT appeared promising, 
results have, unfortunately, been disappointing. The 
best known is the thromboelastograph, a device that 
measures the viscoelastic properties of the clot during 
its formation and subsequent lysis. In general surgi-
cal patients, thromboelastography analysis showed a 
trend toward increased coagulability with progressive 
blood loss and contributed to the identification of two 
patients who required treatment of a coagulopathy.85 
Thromboelastography has a high negative predictive 
value (82%) for bleeding after routine cardiac surgery, 
allowing the differentiation between surgical bleeding 
and coagulopathy. Unfortunately, the positive predic-
tive value of the test is low (41%).86 More studies will 
be required to establish its usefulness in the manage-
ment of MT.
Another instrument, the PFA-100® (Platelet 
Function Analyzer; Dade-Behring, Miami, FL, USA), 
measures an ex-vivo BT in the presence of different 
agonists. The device has been used extensively for the 
diagnosis of hereditary coagulation disorders, particu-
larly von Willebrand’s disease. In patients undergoing 
routine cardiac operations, the PFA was not correlated 
with mediastinal chest drainage.87,88 A Medline search 
on the use of the PFA during MT failed to retrieve any 
relevant references.
B. Treatment of coagulopathy
The treatment of coagulopathy associated with MT is 
not simple. Two approaches are outlined in Table III 
and in Figure 3. Both approaches should be viewed as 
complementary.
TABLE III  Proposals for the administration of hemostatic blood products in the massively transfused patient
                   Presence of clinical bleeding
  Yes No
 Yes Transfusion of FFP and PC Possible transfusion of FFP
  according to the results of and PC if the hemorrhagic risk
  coagulation testing related to the surgical procedure is  
 
   high
Abnormal No Search for a cause other than a No indication to transfuse
coagulation tests*  hemostatic defect
  Re-evaluate the importance of
  red cell transfusion and 
  consider FFP and PC if
  transfusion is massive
  Repeat coagulation tests
 Unknown Transfusion guided by clinical No indication to transfuse
  probability of a specific hemostatic defect Obtain coagulation tests
*Platelet count less than 50,000·mm–3, fibrinogen concentration less than 1.0 g·L–1, prothrombin time (PT) and activated partial throm-
boplastin time (aPTT) more than 1.5 to 1.8 times control. FFP = fresh frozen plasma; PC = platelet concentrate. Adapted from the rec-
ommendations of the “Agence française de sécurité sanitaire des produits de santé” for the transfusion of allogeneic red cells published in 
Transfusion clinique et biologique 2002; 9: 333–56 (article in French).
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1. GOALS OF TREATMENT
The causal diagnosis of MVB remains elusive and 
the clinician must intervene rapidly if the patient is 
to survive. The situation is further complicated by 
the management of risks associated with transfusion, 
mandating that patients receive the smallest number 
of blood products possible. In Canada, in the year 
2000, the risk of human immunodeficiency virus and 
hepatitis C virus transmission was minimal: one in 
four million and one in three million, respectively.89 
However, the aggregate risk of potentially severe 
reactions was much higher: 43.2 per 100,000 red cell 
units and 125.7 per 100,000 platelet pools of five 
units, affecting 337 and 88 recipients, respectively.89 
The most frequent potentially severe outcomes were 
hemolytic reactions and volume overload for red cell 
transfusion and major allergic reactions and bacterial 
contamination for platelet transfusion.89
In general, clinicians assume that all blood products 
are comparable and that the conclusions of studies 
conducted in similarly developed countries can be 
applied locally. We compared the characteristics of 
blood products (PRBC, FFP and platelet concen-
trates) available in Canada and in three European 
countries (Belgium, France and Switzerland; char-
acteristics of allogeneic blood products available as 
Additional Material at www.cja-jca.org). While some 
differences exist, these are minor and unlikely to 
result in clinically significant management disparities 
(Douglas Fish, personal communication).
In light of the above risks, we recommend that blood 
products be transfused to correct a physiologic deficit 
likely to be detrimental to the patient. Obviously, this 
is, most often, not possible in the context of MT, in 
the presence of ongoing hemorrhage for example. 
Hemostatic blood components should be transfused 
mainly to treat a clinical coagulopathy, unless important 
surgical factors justify transfusion, e.g., prior to invasive 
procedures in patients with a known hemostatic defect, 
in neurosurgical procedures where bleeding may have 
catastrophic consequences, etc., (note that the latter 
recommendations are based on expert opinion only).
No prophylactic regimen involving the admin-
istration of FFP and/or platelet concentrates has 
FIGURE 3  The management of massive transfusion in the elective surgical setting 
Reproduced with permission from Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apheresis Sci 2002; 27: 
83–92.
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been shown to be effective in massively transfused 
patients.4,5,77 The prophylactic administration of 
(potentially) unnecessary transfusions exposes patients 
to multiple donors, increases the risks to the patient 
and is unacceptable.90,91 Nonetheless, given the delay 
required to prepare and/or obtain blood products, 
MT associated with evidence of an evolving labora-
tory coagulopathy may warrant ordering of blood 
components that will, then, be readily available to 
treat MVB should it occur.92,93 Whenever possible, the 
use of single donor plasma or platelets is preferred to 
decrease donor exposure.
2. APPROACHES TO THE TREATMENT OF COAGU-
LOPATHY
Figure 3, by Erber et al., summarizes well the use of 
blood and non-blood products involved in the resus-
citation of a bleeding patient.94 Initially, crystalloids 
or colloids are infused to maintain normovolemia. As 
the percentage of blood volumes lost and replaced 
increases, PRBC, FFP and platelets will be required, in 
that order, guided by clinical and laboratory variables. 
Pharmacological agents are usually administered rela-
tively late in the process [protamine sulfate antagonizes 
the effect of excess heparin; desmopressin has been used 
to control hemorrhage, specially after cardiac surgery, 
with varying success; aprotinin has been suggested in 
the context of trauma and MT but its use is not support-
ed by any controlled trial; recombinant activated factor 
VII (rFVIIa) is a promising hemostatic agent under 
investigation but the optimal timing of administration 
of rFVIIa remains to be determined]. While this scheme 
is appealing and applicable in the elective surgical setting 
where bleeding is usually progressive and coagulopathy 
can be monitored and anticipated, the situation can be 
quite different in the traumatized patient.
In the interval between injury and arrival to the hos-
pital, the trauma patient has lost an undefined amount 
of blood that has been replaced, in part, by crystalloids 
or colloids.72 Tissue trauma, shock, tissue anoxia and 
hypothermia contribute to the development of DIC 
and the results of coagulation testing are not immedi-
ately available. Clinicians are called upon to intervene 
rapidly in a very unclear and unstable situation.
Basic recommendations include the maintenance 
of normothermia and correction of a low hemo-
globin concentration. Maintaining a normal body 
temperature is a relatively simple and probably one 
of the most effective strategies of blood conserva-
tion. Unfortunately, it can easily be overlooked in the 
trauma setting. When a hypothermic patient bleeds 
without an apparent surgical cause, restoration of 
temperature towards normal should be a first-line 
intervention. Correction of the hypothermia-induced 
hemostatic defect can be expected as soon as the 
patient is rewarmed.
A low hemoglobin concentration should be cor-
rected prior to the administration of hemostatic blood 
products, in view of normalizing hemostasis in bleed-
ing patients. When circumstances allow, allogeneic 
RBC should be transfused one unit at a time and the 
effects of transfusion on hemostasis monitored before 
administering supplemental units. The optimal hemo-
globin concentration to sustain hemostasis in the con-
text of MT remains unknown but is probably higher 
than that required for oxygen transport and delivery.
The use of platelets and/or FFP should depend on 
the results of coagulation testing and clinical judg-
ment. A markedly prolonged PT and aPTT suggests a 
coagulation factor deficiency and is best treated with 
FFP. Decreased levels of fibrinogen will also require 
treatment with FFP. FFP should be administered in 
doses large enough to increase coagulation factor lev-
els and maintain them above critical levels. Doses rang-
ing from 5 to 20 mL·kg–1 have been recommended. 
In the average adult, four units of FFP (800 to 1,000 
mL) should suffice initially but additional bolus doses 
should be administered according to ongoing blood 
losses and transfusions.6 As shown in Figure 4, it is 
important to administer sufficient bolus doses of FFP 
to maintain adequate concentrations of coagulation 
factors. Further, using a three compartment dynamic 
computer simulation, Hirshberg et al. suggest that, in 
FIGURE 4  Simulation of relative plasma volume according to 
mode of fresh frozen plasma (FFP) supplementation 
Reproduced with permission from Hiippala S. Replacement of 
massive blood loss. Vox Sang 1998; 74: 399–407.
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trauma patients with exsanguinating hemorrhage, FFP 
should be given rapidly (with the first units of PRBC 
replacement) in order to effectively prevent dilutional 
coagulopathy.72
If the fibrinogen concentration remains below 1.0 
g·L–1 despite therapy with FFP, the administration of 
cryoprecipitate, a concentrated source of fibrinogen, 
factor VIII, factor XIII and von Willebrand factor 
may be indicated95 despite the associated infectious 
risks (ten to 20 units - containing 5 mL each - will be 
required). In Europe specially, cryoprecipitates are no 
longer available and, when fibrinogen substitution is 
required, virus-inactivated fibrinogen preparations are 
administered.
Platelets should be administered to correct a 
clinical coagulopathy associated with a decreased 
platelet count and/or platelet function. Clinicians 
must remember that platelet counts will decrease in 
a majority of massively transfused patients but that 
not all patients will bleed excessively as a result of 
thrombocytopenia. Other hemostatic anomalies may 
warrant a more urgent (a marked prolongation of the 
PT and aPTT) or concurrent (a decreased fibrinogen 
level) correction.
From the time PRBC have replaced whole blood, 
there is laboratory and clinical evidence in the lit-
erature that FFP may be required prior to platelet 
concentrates to treat a coagulopathy.3,6,8,73 On the 
other hand, two studies have shown that survival in 
massively transfused trauma patients is associated with 
the increased transfusion of platelet concentrates.41,96 
One may postulate that a more aggressive control of 
coagulopathy was beneficial in these patients, a situa-
tion somewhat analogous to the benefits derived from 
early goal-directed therapy in patients with severe 
sepsis and septic shock.97 Unfortunately, at present, 
no monitor allows clinicians to identify which patient 
is likely to benefit from the increased transfusion of 
hemostatic blood components (such as platelets or 
FFP).
Several animal experiments, case reports and case 
series report the successful use of rFVIIa to treat bleed-
ing that could not be controlled by the administration of 
hemostatic blood components.98–106 Originally, rFVIIa 
was developed to treat hemophiliacs with inhibitors to 
exogenous factor VIII and its use has been extended 
to the correction of several hemostatic defects.107 Since 
factor VII must interact with tissue factor to initiate 
the generation of thrombin, coagulation occurs at the 
site of injury108 and the risk of thromboembolic effects 
appears minimal.109 The initial results with this novel 
hemostatic agent for “rescue” therapy of MVB are 
impressive and warrant the conduct of randomized 
controlled trials to evaluate further the efficacy and 
safety of this expensive drug.110,111
TABLE IV  Massive transfusion: the main differences between elective surgery and trauma
 Elective surgery Trauma
Tissue trauma Controlled Massive and uncontrolled
Initiation of massive No delay between hemorrhage The interval between
transfusion and initiation of treatment hemorrhage and treatment can
  vary widely
Volume status/shock Normovolemia is maintained Hypovolemia and shock are
 and shock is avoided frequent
Temperature Normothermia is maintained Hypothermia is frequent
Monitoring of hemostasis Ongoing. Anticipation of Late. Laboratory tests are
 hemostatic defects is possible obtained when coagulopathy is installed
Coagulopathy More often related to Often related to disseminated
 decreased coagulation factors intravascular coagulation
Treatment of coagulopathy Correction of anemia Correction of tissue
 FFP and platelets as hypoperfusion
 determined by laboratory tests Correction of hypothermia
  Correction of anemia
  Platelets and FFP
  as determined by laboratory tests
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IV. Conclusions
Our first objective was to review the pathophysiology 
of coagulopathy in massively transfused, adult and pre-
viously hemostatically competent patients in both the 
elective surgical and trauma settings. The pathophysi-
ology is complex and coagulopathy associated with 
MT requires a multidisciplinary approach involving 
anesthesiologists, blood bankers, hematologists, labo-
ratory specialists and surgeons. In the trauma patient, 
DIC secondary to tissue injury and anoxia often com-
plicates the management of MT. As a result, it is often 
difficult to ascertain the exact cause of MVB. The 
“classic” view that thrombocytopenia is responsible 
for the majority of bleeding complications in mas-
sively transfused patients should be abandoned.93 As 
we have seen, decreased levels of platelets and coagu-
lation factors cannot be predicted by dilution alone. 
Coagulopathy associated with MT and surgery is an 
intricate, multicellular and multifactorial event. While 
the interaction between platelets, fibrinogen and red 
cells is particularly important, the contribution of fluid 
replacement therapy, hypothermia and coagulation 
factor deficiency must not be overlooked.
Our second objective was to review the evidence 
for strategies used to manage coagulopathy in both 
the elective surgical and trauma settings. Whether 
for elective surgery or for the management of trauma 
patients, reliable bedside monitors of hemostasis are 
needed urgently. By assisting clinicians in making the 
correct diagnosis in a timely manner, monitors will 
contribute to the optimal use of blood products.
Times have changed, blood products have changed, 
and so has the management of the bleeding patient. 
Therapy should take into account all the factors known 
to affect hemostasis in these patients. Transfusion of 
blood components should be based on appropriate 
hematological testing and initiated mainly in those 
patients who bleed actively. Nevertheless, a standard-
ized management of MVB may not always be possible 
in massively bleeding patients, especially in the context 
of trauma.
The situation appears to be different in the elec-
tive surgical situation. Tissue trauma is more con-
trolled, normovolemia can usually be maintained, 
tissue anoxia is avoided and there is more time to 
monitor coagulation variables and anticipate deficits. 
In this context, coagulopathy is more often related to 
decreased coagulation factors and best treated initially 
with FFP. The main differences between elective sur-
gery and trauma are summarized in Table IV.
Finally, anesthesiologists tend to focus on hemor-
rhage and MT that occur as an immediate consequence 
of trauma or surgery. Yet, two other important consid-
erations should be kept in mind. First, it is important 
to realize that many pre-existing bleeding disorders are 
clinically silent and only manifest at times of hemostatic 
stress such as trauma and major surgery.112 Thus, a 
postoperative assessment may be warranted in patients 
with a history or clinical examination suggestive of 
such a bleeding disorder. Second, in the postoperative 
period, many of these patients will experience throm-
botic complications112 related to the consumption of 
coagulation factors associated with DIC. Once the ini-
tial, hemorrhagic, phase of coagulopathy is controlled, 
efforts should be directed towards the prevention of 
later, potentially disastrous thrombotic complications. 
Only then will the management of coagulopathy associ-
ated with MT be complete.
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Addendum
Our review article on the management of massive trans-
fusion and the associated disorders of hemostasis, was 
first published in the Canadian Journal of Anesthesia in 
April 2004 (Can J Anesth 2004; 51: 293–310). Written 
by members of the Groupe d’Intérêt en Hémostase 
Périopératoire, we felt the article would be an appropri-
ate contribution to the Group's Supplement on “The 
management of bleeding and thrombosis in the peri-
operative period: the anesthesiologist’s perspective”. 
However, given the relatively short time period elapsed 
since the initial appearance of the review, we also felt 
that a revised publication would have been redundant 
at this time,  little new original information having been 
published in the interim. 
Nevertheless, one important article on the use of 
recombinant activated factor VII (rFVIIa) has been 
published recently and warrants additional comment. 
The article by Boffard et al. reports the results of 
two parallel randomized, placebo-controlled, double-
blind clinical trials on the use of rFVIIa as adjunctive 
therapy to control bleeding in severely injured trauma 
patients.1
Patients received either rFVIIa (three doses for a 
total of 400 µg·kg–1) or an equal volume of placebo 
and were stratified to blunt or penetrating injury, 
hence the two trials. The primary endpoint was the 
total number of red blood cell (RBC) units transfused 
from start of treatment to 48 hr. Secondary endpoints 
included requirement for other transfusion products 
(fresh frozen plasma, platelets and cryoprecipitates); 
mortality; days on the ventilator and days in the inten-
sive care unit. Safety outcomes included frequency and 
timing of adverse events, and changes in coagulation 
laboratory variables. In addition, the authors studied 
a composite endpoint of death and critical complica-
tions [multiple organ failure (MOF) and acute respira-
tory distress syndrome (ARDS)].
